24 Jun

Supreme Court snub confirms Amarin’s patent disaster

The significant commercial damage resulting from Amarin’s unexpected loss of its Vascepa patents, now confirmed after the Supreme Court refused to hear the company’s case, is a stark reminder of the dangers of taking key biopharma IP assets all the way to trial

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth